ABSTRACT
The Covid-19 global pandemic has reshaped the requirements of healthcare sectors worldwide. Following the exposure risks associated with Covid-19, this paper aims to design, optimise, and validate a wearable medical device that reduces the risk of transmission of contagious droplets from infected patients in a hospital setting. This study specifically focuses on those receiving high-flow nasal oxygen therapy. The design process consisted of optimising the geometry of the visor to ensure that the maximum possible percentage of harmful droplets exhaled by the patient can be successfully captured by a vacuum tube attached to the visor. This has been completed by deriving a number of concept designs and assessing their effectiveness, based on numerical analysis, computational fluid dynamics (CFD) simulations and experimental testing. The CFD results are validated using various experimental methods such as Schlieren imaging, particle measurement testing and laser sheet visualisation. Droplet capturing efficiency of the visor was measured through CFD and validated through experimental particle measurement testing. The results presented a 5% deviation between CFD and experimental results. Also, the modifications based on the validated CFD results improved the visor effectiveness by 47% and 38% for breathing and coughing events, respectively © 2022 The Author(s)
ABSTRACT
The Covid-19 global pandemic has reshaped the requirements of healthcare sectors worldwide. Following the exposure risks associated with Covid-19, this paper aims to design, optimise, and validate a wearable medical device that reduces the risk of transmission of contagious droplets from infected patients in a hospital setting. This study specifically focuses on those receiving high-flow nasal oxygen therapy. The design process consisted of optimising the geometry of the visor to ensure that the maximum possible percentage of harmful droplets exhaled by the patient can be successfully captured by a vacuum tube attached to the visor. This has been completed by deriving a number of concept designs and assessing their effectiveness, based on numerical analysis, computational fluid dynamics (CFD) simulations and experimental testing. The CFD results are validated using various experimental methods such as Schlieren imaging, particle measurement testing and laser sheet visualisation. Droplet capturing efficiency of the visor was measured through CFD and validated through experimental particle measurement testing. The results presented a 5% deviation between CFD and experimental results. Also, the modifications based on the validated CFD results improved the visor effectiveness by 47% and 38% for breathing and coughing events, respectively [ FROM AUTHOR]
ABSTRACT
The Covid-19 global pandemic has reshaped the requirements of healthcare sectors worldwide. Following the exposure risks associated with Covid-19, this paper aims to design, optimise, and validate a wearable medical device that reduces the risk of transmission of contagious droplets from infected patients in a hospital setting. This study specifically focuses on those receiving high-flow nasal oxygen therapy. The design process consisted of optimising the geometry of the visor to ensure that the maximum possible percentage of harmful droplets exhaled by the patient can be successfully captured by a vacuum tube attached to the visor. This has been completed by deriving a number of concept designs and assessing their effectiveness, based on numerical analysis, computational fluid dynamics (CFD) simulations and experimental testing. The CFD results are validated using various experimental methods such as schlieren imaging, particle measurement testing and laser sheet visualisation. Droplet capturing efficiency of the visor was measured through CFD and validated through experimental particle measurement testing. The results presented a 5% deviation between CFD and experimental results. Also, the modifications based on the validated CFD results improved the visor effectiveness by 47% and 38% for breathing and coughing events, respectively
ABSTRACT
Since the coronavirus disease 2019 (COVID-19) pandemic emerged in November 2019, various international guidelines and local protocols have been published to assist clinicians face the pandemic effectively. Medical and ventilatory strategies have evolved and researchers have come out with multiple studies and solutions within a short period of time. The patient's best interest is always the goal of the management. We present a case report of COVID-19 pneumonia in a patient with underlying Eisenmenger syndrome and the potential benefits of high-flow nasal oxygen therapy in this patient.
ABSTRACT
INTRODUCTION: The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection resulted in significant worldwide morbidity and mortality. The aim of our study was to evaluate the results of laboratory tests performed on patients on admission to the hospital between groups of patients requiring and not requiring oxygen supplementation, and to find predictive laboratory indicators for the use of high-flow nasal oxygen therapy (HFNOT)/continuous positive airway pressure (CPAP)/bilevel positive airway pressure (BPAP). MATERIALS AND METHODS: We retrospectively analysed the data of consecutive patients hospitalised in the Pulmonology Department of the Temporary COVID Hospital in Poznan from February to May 2021. On admission to the department, the patients had a panel of laboratory blood tests. RESULTS: The study group consisted of 207 patients with a mean age of 59.2 ± 15.0 years of whom 179 (72%) were male. During hospitalisation, oxygen supplementation was required by 87% of patients. Patients requiring oxygen supplementation and/or the use of HFNOT/CPAP/BPAP had lower lymphocyte counts and higher levels of urea, C-reactive protein, D-dimer, troponin, glucose, lactate dehydrogenase (LDH) as well as higher white blood cell and neutrophil counts, The parameter that obtained the highest area under curve value in the receiver operator curve analysis for the necessary use of HFNOT/CPAP/BPAP or CPAP/BPAP was LDH activity. CONCLUSIONS: Among the basic parameters assessed on admission to the temporary hospital, LDH activity turned out to be the most useful for assessing the need for CPAP/BPAP active oxygen therapy. Other parameters that may be helpful for predicting the need for HFNOT/CPAP/BPAP are serum levels of urea, D-dimer and troponin.